- Home
- GEOS vs DMAC Comparison
GEOS vs DMAC Comparison
Compare GEOS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEOS
- DMAC
- Stock Information
- Founded
- GEOS 1980
- DMAC 2000
- Country
- GEOS United States
- DMAC United States
- Employees
- GEOS N/A
- DMAC N/A
- Industry
- GEOS Industrial Machinery/Components
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GEOS Industrials
- DMAC Health Care
- Exchange
- GEOS Nasdaq
- DMAC Nasdaq
- Market Cap
- GEOS 72.9M
- DMAC 178.0M
- IPO Year
- GEOS 1997
- DMAC N/A
- Fundamental
- Price
- GEOS $12.40
- DMAC $3.63
- Analyst Decision
- GEOS
- DMAC Strong Buy
- Analyst Count
- GEOS 0
- DMAC 2
- Target Price
- GEOS N/A
- DMAC $8.00
- AVG Volume (30 Days)
- GEOS 500.4K
- DMAC 325.9K
- Earning Date
- GEOS 08-07-2025
- DMAC 08-06-2025
- Dividend Yield
- GEOS N/A
- DMAC N/A
- EPS Growth
- GEOS N/A
- DMAC N/A
- EPS
- GEOS N/A
- DMAC N/A
- Revenue
- GEOS $116,542,000.00
- DMAC N/A
- Revenue This Year
- GEOS N/A
- DMAC N/A
- Revenue Next Year
- GEOS N/A
- DMAC N/A
- P/E Ratio
- GEOS N/A
- DMAC N/A
- Revenue Growth
- GEOS N/A
- DMAC N/A
- 52 Week Low
- GEOS $5.51
- DMAC $2.98
- 52 Week High
- GEOS $18.99
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- GEOS 55.56
- DMAC 44.55
- Support Level
- GEOS $12.60
- DMAC $3.48
- Resistance Level
- GEOS $14.38
- DMAC $3.88
- Average True Range (ATR)
- GEOS 1.80
- DMAC 0.26
- MACD
- GEOS -0.32
- DMAC 0.00
- Stochastic Oscillator
- GEOS 38.67
- DMAC 30.10
About GEOS Geospace Technologies Corporation (Texas)
Geospace Technologies Corp is engaged in designing and manufacturing seismic instruments and non-seismic equipment used in the oil and gas industry. The company has three different segments: oil and gas markets, adjacent markets, and emerging markets. The oil and gas markets segment, which accounts for the majority of the company's revenue, includes traditional exploration products, wireless exploration products, and reservoir characterization products and services. The adjacent markets business is closely tied to the oil and gas markets and includes imaging products and industrial products. The company operates globally across Asia, Canada, Europe, the United States, South America, Mexico, and other regions with a majority of its revenue being generated within the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.